Cargando…

Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients

AIM: To understand the proportion of uHCC (unresectable hepatocellular carcinoma) patients who achieve successful conversion resection in a high-volume setting with state of the art treatment options. METHODS: We retrospectively reviewed all HCC patients hospitalized to our center from June 1(st), 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Bo, Shi, Xuetao, Cui, Kai, Li, Zhongchao, Li, Lei, Liu, Zhaogang, Zhang, Chengsheng, Sun, Pengfei, Zhong, Jingtao, Sun, Zhicheng, Chang, Zhibin, Ma, Zhao, Gordon-Weeks, Alex, Li, Mingming, Zhao, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199571/ https://www.ncbi.nlm.nih.gov/pubmed/37210519 http://dx.doi.org/10.1186/s12885-023-10955-7

Ejemplares similares

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
por: Zhang, Bo, et al.
Publicado: (2022)

Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells
por: Zhong, Jingtao, et al.
Publicado: (2018)

Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma
por: Zhou, Yinghong, et al.
Publicado: (2020)

T7 peptide cytotoxicity in human hepatocellular carcinoma cells is mediated by suppression of autophagy
por: Liu, Feng, et al.
Publicado: (2019)

RAB9A Plays an Oncogenic Role in Human Liver Cancer Cells
por: Sun, Pengfei, et al.
Publicado: (2020)

A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature
por: Zhang, Chengsheng, et al.
Publicado: (2016)

Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage III gastric cancer: a case report
por: Jian, Dan, et al.
Publicado: (2021)

Efficacy of conversion therapy on initially unresectable locally advanced rectal cancer
por: Liu, Tianyu, et al.
Publicado: (2021)

MiR-98 modulates macrophage polarization and suppresses the effects of tumor-associated macrophages on promoting invasion and epithelial–mesenchymal transition of hepatocellular carcinoma
por: Li, Lei, et al.
Publicado: (2018)

The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization
por: Sun, Bo, et al.
Publicado: (2022)

Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
por: Sun, Hui-Chuan, et al.
Publicado: (2021)

Helicobacter pylori causes delayed gastric emptying by decreasing interstitial cells of Cajal
por: Liu, Bin, et al.
Publicado: (2021)

Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
por: Long, Zuoyao, et al.
Publicado: (2023)

Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma
por: Chen, Kang, et al.
Publicado: (2022)

Conversion surgery for initially unresectable extrahepatic biliary tract cancer
por: Oh, Moon Young, et al.
Publicado: (2021)

Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro)
por: Huang, Shujie, et al.
Publicado: (2022)

LINC-26. ORAL VINORELBINE IN PROGRESSIVE UNRESECTABLE LOW-GRADE GLIOMA
por: Cappellano, Andréa M, et al.
Publicado: (2020)

Measurement of the Photothermal Conversion Efficiency of CNT Films Utilizing a Raman Spectrum
por: Liu, Yu, et al.
Publicado: (2022)

Self-frequency-conversion nanowire lasers
por: Yi, Ruixuan, et al.
Publicado: (2022)

Fifty-five Consecutive Laparoscopic Appendectomy Procedures Without Conversion
por: Palesty, J. Alexander, et al.
Publicado: (2004)

Conversion resection for patients with hepatocellular carcinoma and inferior vena cava tumor thrombus: a consecutive case series
por: Zhang, Xiaoyun, et al.
Publicado: (2022)

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
por: Luo, Laihui, et al.
Publicado: (2022)

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2023)

Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
por: Li, Binkui, et al.
Publicado: (2021)

Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
por: Zhao, Shoujie, et al.
Publicado: (2020)

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
por: Yi, Yong, et al.
Publicado: (2022)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
por: Gan, Leijuan, et al.
Publicado: (2023)

Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis
por: Pei, Yinxuan, et al.
Publicado: (2022)

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
por: Qu, Wei-Feng, et al.
Publicado: (2022)

Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma
por: Zhao, Shoujie, et al.
Publicado: (2020)

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
por: Shao, Wenbo, et al.
Publicado: (2019)

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma
por: Yanagimoto, Hiroaki, et al.
Publicado: (2020)

Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
por: Wu, Jia-Lin, et al.
Publicado: (2023)

Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
por: Zhu, Xiao-Dong, et al.
Publicado: (2022)

Transduodenal ampullectomy for ampullary tumors – single center experience of consecutive 26 patients
por: Hong, Sarang, et al.
Publicado: (2018)

Safety of tracheotomy in neutropenic patients: A retrospective study of 26 consecutive cases
por: Blot, F., et al.
Publicado: (1995)

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Li, Lin, et al.
Publicado: (2018)

Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy
por: Peng, Jianhong, et al.
Publicado: (2021)

Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?
por: Zhang, Ze-Feng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_apfcnh7mappusjramlbspa1ikn